NCCN Participates in Asia Consensus Statement Meeting in South Korea
Jonathan Larsen, MPP, Manager, Global Business Development
In September, James L. Mohler, MD, Roswell Park Cancer Institute, chair of the NCCN Prostate Cancer Panel, travelled to Incheon, South Korea to represent the National Comprehensive Cancer Network® (NCCN®) on a panel of multidisciplinary specialists from China, India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Thailand in consensus discussions to successfully update the 2011 Asia Consensus Statement for Prostate Cancer. These discussions comprise scientific descriptions and analyses of variations in care across numerous regions in Asia.
The Asia Consensus Statement for Prostate Cancer is a manuscript designed to provide clinical resources for Asian specialists who are involved in the management of patients with prostate cancer within the represented countries. In addition to NCCN, the Asia Pacific Society of Uro-Oncology, Asian Pacific Prostate Society, and Japan Society of Clinical Oncology collaborated on this update, which is scheduled to be available in early 2014.
“In the past two years there has been amazing progress in better understanding regional needs regarding prostate cancer across Asia,” said Dr. Mohler. “Particularly impressive is the increasing amount of research about prostate cancer that helps to inform the update of the NCCN Asia Consensus Statement, ultimately aiding clinicians regionally in determining appropriate and effective care.”
According to Dr. Mohler, the meeting participants pointed to growing evidence that androgen deprivation therapy may be more effective and result in fewer side effects in Asian men than in the West and that overall incidence and mortality from prostate cancer is rising in Asia. Additionally, the opportunity for Asian experts to learn from the experience in the United States regarding the risks and benefits of Prostate-Specific Antigen (PSA) Testing was highlighted.